All In Biotech

Drug Trial Radar · NCT07824193

Drug-drug Interaction Study of Clemizole (EPX-100) in Healthy Participants

A Phase 1, 3-Part Study to Evaluate the Effect of CYP3A4 Inhibition and Induction on the Pharmacokinetics of Clemizole and the Effect of Clemizole on the Pharmacokinetics of CYP2C19, CYP3A4, and CYP2B6 Substrates in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

54

Actual

Start

Jan 15, 2025

Primary completion

Apr 3, 2025

Study completion Apr 3, 2025

Sponsor

Lead sponsor
EpygenixIndustry
Sponsor type
Industry
Collaborators
Harmony Biosciences Management, Inc.
First posted
Sep 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a 3-part, drug-drug interaction study in healthy participants. Each part is designed as a 2-period, fixed-sequence and can be conducted concurrently. Part 1 will assess the effect of itraconazole on the pharmacokinetics (PK) of EPX-100. Part 2 will assess the effect of phenytoin on the PK of EPX-100. Part 3 will assess the effect of EPX-100 on the PK of omeprazole, midazolam, and bupropion.

Conditions

  • Drug Drug Interaction

Interventions

  • EPX-100Drug

    Oral solution

  • ItraconazoleDrug

    Oral solution

  • PhenytoinDrug

    Phenytoin sodium extended-release capsules

  • OmeprazoleDrug

    Delayed-release capsule

  • MidazolamDrug

    Midazolam hydrochloride (HCl) syrup

  • BupropionDrug

    Bupropion HCl tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under The Concentration-time Curve (AUC), from Time 0 to the Last Observed Non-zero Concentration (AUC0-t) Of EPX-100Time frame: Up to Day 15
  2. AUC From Time 0 extrapolated to infinity (AUC0-inf) of EPX-100Time frame: Up to Day 15
  3. Maximum Observed Concentration (Cmax) of EPX-100Time frame: Up to Day 15
  4. AUC0-t of OmeprazoleTime frame: Up to Day 15
  5. AUC0-inf of OmeprazoleTime frame: Up to Day 15
  6. Cmax of OmeprazoleTime frame: Up to Day 15
  7. AUC0-t of MidazolamTime frame: Up to Day 15
  8. AUC0-inf of MidazolamTime frame: Up to Day 15
  9. Cmax of MidazolamTime frame: Up to Day 15
  10. AUC0-t of BupropionTime frame: Up to Day 19
  11. AUC0-inf of BupropionTime frame: Up to Day 19
  12. Cmax of BupropionTime frame: Up to Day 19

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Celerion

    Tempe, Arizona

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.